Human FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

Control of Regulatory T Cell Development by the Transcription Factor Foxp3

Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187

Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745

The Immune Landscape of Cancer

Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870

Signaling by intrathymic cytokines, not T cell antigen receptors, specifies CD8 lineage choice and promotes the differentiation of cytotoxic-lineage T cells

Park, J., Adoro, S., Guinter, T. I., Erman, B., Alag, A., Catálfamo, M., Kimura, M. Y., Cui, Y., Lucas, P. J., Gress, R. E., et al. (2010) · Nature Immunology · doi:10.1038/ni.1840 · Cited by 5,835

Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases

Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1151 · Cited by 5,608

Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294

Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade

Charoentong, P., Finotello, F., Angelova, M., Mayer, C., Efremova, M., Rieder, D., Hackl, H., & Trajanoski, Z. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.019 · Cited by 5,041

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025

The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3

Bennett, C. L., Christie, J., Ramsdell, F., Brunkow, M., Ferguson, P., Whitesell, L., Kelly, T., Saulsbury, F., Chance, P., & Ochs, H. (2001) · Nature Genetics · doi:10.1038/83713 · Cited by 3,576

The Role of EBV Infection and Epigenetic Factors in Radioresistance of Colorectal Cancer

李元麒, Huang, T., & Zhou, Y. (2026) · Methods in molecular biology · doi:10.1007/978-1-0716-5264-0_10

OX40+ regulatory T cells suppress neoadjuvant chemotherapy response in NSCLC and reversed by combination of PD-1 blockade therapy

Zhang, J., Liu, R., Hui, Q., Chen, Y., Luo, J., Wang, Y., Ye, Z., Ren, X., & Hui, Z. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.109458

Beyond suppression: the plasticity, dysfunction, and therapeutic reprogramming of regulatory T cells in inflammatory bowel disease

Shao, Y., Yu, S., Zhang, M., Huang, Y., Dou, Z., Tian, B., & Lu, J. (2026) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiag067

SRSF3 determines T reg cell fate in antitumor immunity and autoimmunity

Jia, R., Guo, J., Yan, L., Lin, C., Jia, J., Shao, J., Zhang, D., Liu, N., & Chen, W. (2026) · Science Advances · doi:10.1126/sciadv.aeh1671

Epigenetic and metabolic reprogramming in autoimmune rheumatology: toward immune tolerance reprogramming

Al-Ewaidat, O. A., & Naffaa, M. M. (2026) · Exploration of Immunology · doi:10.37349/ei.2026.1003255

Advancements in cancer immunotherapy: Targeting the tumor immune microenvironment (TIME)

Sadar, S. S., Polshettiwar, S. A., Phalak, C., Walhekar, V., Chaher, S., & Lagad, V. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45717-3.00015-5

Stress-induced IL-6 regulation in pediatric bone growth disorders: current insights and therapeutic strategies

Sohail, Z., Hadi, N. B. A., Rehman, A., Asghar, M., & Zaman, F. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1833900

GREM1/FGFR1-activated myofibroblasts induce immunosuppression and accelerate metastasis in high-grade serous ovarian cancer

Li, R., Huang, X., Chen, Y., Chen, X., Yang, Y., Liu, Y., Bai, B., Meng, F., Li, Y., & Ning, Y. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2529786123

Tumor-adapted regulatory T cells: Molecular reprogramming, immune suppression, and therapeutic targeting in cancer

Fayyad‐Kazan, M. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12209-8

TNFRSF18+ Regulatory T Cells as a Potential Biomarker of Immunotherapeutic Outcomes in Immunosuppressed Colon Cancer

Dai, K., Ye, L., Jin, Z., Wang, J., & Chen, L. (2026) · Human Mutation · doi:10.1155/humu/5366828

Stable and Functional Regulatory T Cells for Adoptive Cell Therapy

Mikami, N. (2026) · Barrier Immunity · doi:10.1002/dni2.70013

Mitochondrial gene expression-based model for the prediction of thyroid cancer prognosis

Zha, W., Li, J., Li, Y., Li, H., Yang, X., Liu, Y., Wang, C., Xu, Y., Li, X., Wang, X., et al. (2026) · Endocrine Connections · doi:10.1530/ec-26-0245

Biomaterial-mediated immunomodulation of regulatory T cells in cancer

Hengen, A. C., Kolon, H. H., & Ackun‐Farmmer, M. A. (2026) · Biomaterials Science · doi:10.1039/d6bm00653a

Destabilization of intratumor Tregs by CTLA-4 engagement confers anti-CTLA-4-driven immunotherapyPreprint

Liu, N., Xu, J., Ku, W. L., Chen, W., Cao, Y., Kazmi, R., Jin, W., Gauthier, T., Luo, S., Shen, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.28.741328

eIF6 affects the occurrence and development of esophageal cancer

Huang, C.-G., Zhou, X., Huang, R., Zhang, H.-L., Li, C., Du, F., Lei, H., Dai, Q., & Yang, Z. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12268-x

Biomarker-driven neoadjuvant immunotherapy in triple-negative breast cancer: emerging therapeutic targets FOXP3 and WT1

Zhang, Z., Zhao, R., Hu, Y., Xie, Q., Yu, Y., Li, K., Ding, Z., & Wang, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1851289

Reprogramming Adenosine‐Driven Tumor Immunosuppression With a Carrier‐Free Nanoplatform for Self‐Amplifying Antitumor Immunity

Ming, Y., Xiang, Z., Zhao, M., & Chen, X. S. (2026) · Small · doi:10.1002/smll.75164

BNT162b2 mRNA vaccination activates spike-reactive regulatory T cells in humans

Shinwari, N., Xue, X., Lu, D., Chua, C., Iwamoto, Y., Masuo, Y., Sekito, S., Akiyama, D., Murakawa, Y., Hashiguchi, T., et al. (2026) · International Immunology · doi:10.1093/intimm/dxag045

The thymus gland is a target and maintainer of amyotrophic lateral sclerosis pathophysiology

Lemos, J. P., Stockholm, D., Dinatale, B., Chaves, A. S., Pezet, S., Carvalho, V. F., Pérez, A. R., Mendes‐da‐Cruz, D. A., Savino, W., & Smeriglio, P. (2026) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2026.101323

Recent advances in molecular mechanisms to improve the efficacy of CAR-T cell therapy for viral diseases, cancer, and autoimmune diseases

Marei, H. E. S., Pozzoli, G., Caratelli, S., & Cenciarelli, C. (2026) · Stem Cell Research & Therapy · doi:10.1186/s13287-026-05266-0

Targeting the Th17/Treg axis: from immunological insights to therapeutic avenues in atherosclerosis

Qin, Z., Chen, S., Lyu, Z., Zhou, F., Liu, L., Ai, Q., & Zeng, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1923083

Sustained microparticle-mediated intracellular immunomodulation enhances tolerogenic dendritic cell stability and antigen-specific Treg induction

Jia, S., Weiser, Z., Rajasekaran, M., DiMitri, L. G., & Deak, P. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1897468

Spatial transcriptomics reveals immune remodeling in lymph nodes of gastric adenocarcinoma

Suwatthanarak, T., Nampoolsuksan, C., Tanjak, P., Thanormjit, K., Acharayothin, O., Chaiboonchoe, A., Suwatthanarak, T., Pithukpakorn, M., Chalermwai, W. V., Swangsri, J., et al. (2026) · Clinical & Experimental Metastasis · doi:10.1007/s10585-026-10429-7

Cellular Therapy in Inflammatory Bowel Diseases

Majna, S., Brezina, B., Sharip, M. T., Subramanian, S., & Noor, N. M. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16100517

Regulatory T cell heterogeneity: who they are, where they come from, and where they go

Yang, F., Ikeda, Y., Guo, Z., & Bednar, K. J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1929923

Treg and Oxidative Stress Biomarker Profiles in Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Todorova, Y., Dimitrova, R., Kalfova, T., Петров, С. В., Bozhkova, M., Ivanovska, M., Dudova, D., Murdjeva, M., Taskov, H. B., Maes, M. H. J., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27219422

BindingDB Entry 50019203: Discovery of Novel 3-Phenylpiperidine Derivatives Targeting the β-Catenin/B-Cell Lymphoma 9 Interaction as a Single Agent and in Combination with the Anti-PD-1 Antibody for the Treatment of Colorectal Cancer.

BindingDB (2024) · UC San Diego · doi:10.7270/q2pn99z2

BindingDB Entry 50009674: Novel Benzohydroxamate-Based Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitors Bearing a Pentaheterocyclic Scaffold: Design, Synthesis, and Biological Evaluation.

BindingDB (2021) · UC San Diego · doi:10.7270/q2kp85mz

T cell–mediated depletion of intratumoral regulatory T cells using a CCR8xCD3 T cell–engaging bispecific antibody (TCB) promotes antitumor immunity in preclinical mouse models

Wang, B., Ishizuka, I. E., Esen, E., Li, J., Chiu, C., Sun, Y., Lin, Z., Seshasayee, D., Kusi, A., Zhong, Y., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.aea7127

Targeting N-acetyltransferase 10 reprograms Treg function to enhance anti–PD-1 immunotherapy sensitivity in murine lung tumors

Qi, X., Cui, D., Li, X., Fu, W., Ma, H., Guo, W., Wang, J., Song, J., 马, 嘉., Yang, J., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci189034

Human FOXP 3+ T regulatory cell heterogeneity

Mohr, A., Malhotra, R., Mayer, G., Gorochov, G., & Miyara, M. (2018) · Clinical & Translational Immunology · doi:10.1002/cti2.1005 · Cited by 88

Defining Human Regulatory T Cells beyond FOXP3: The Need to Combine Phenotype with Function

Gootjes, C., Zwaginga, J. J., Roep, B. O., & Nikolić, T. (2024) · Cells · doi:10.3390/cells13110941 · Cited by 48

The role of gp130-related cytokines in the modulation of human regulatory T cell function

Bartolucci, S. (2019) · doi:10.82308/7148

FOXP3+ regulatory T cells and their functional regulation

Li, Z., Li, D., Tsun, A., & Li, B. (2015) · Cellular & Molecular Immunology · doi:10.1038/cmi.2015.10 · Cited by 290

The role of FOXP3+ regulatory T cells in human autoimmune and inflammatory diseases

Mohr, A., Atif, M., BALDERAS, R. S., Gorochov, G., & Miyara, M. (2019) · Clinical & Experimental Immunology · doi:10.1111/cei.13288 · Cited by 90